The relative in vitro antiviral activities of three related nucleoside carboxamides, ribavirin (1-3-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), tiazofurin (2-3-D-ribofuranosylthiazole-4-carboxamide), and selenazole (2-p-D-ribofuranosylselenazole-4-carboxamide), were studied against selected DNA and RNA viruses. Although the activity of selenazole against different viruses varied, it was significantly more potent than ribavirin and tiazofurin against all tested representatives of the families Paramyxoviridae (parainfluenza virus type 3, mumps virus, measles virus), Reoviridae (reovirus type 3), Poxviridae (vaccinia virus), Herpesviridae (herpes simplex virus types 1 and 2), Togaviridae (Venezuelan equine encephalomyelitis virus, yellow fever virus, Japanese encephalitis virus), Bunyaviridae (Rift Valley fever virus, sandfly fever virus [strain Sicilian], Korean hemorrhagic fever virus), Arenaviridae (Pichinde virus), Picornaviridae (coxsackieviruses B1 and B4, echovirus type 6, encephalomyocarditis virus), Adenoviridae (adenovirus type 2), and Rhabdoviridae (vesicular stomatitis virus). The antiviral activity of selenazole was also cell line dependent, being greatest in HeLa, Vero-76, and Vero E6 cells. Selenazole was relatively nontoxic for Vero, Vero-76, Vero E6, and HeLa cells at concentrations of up to 1,000 ,g/ml. The relative plating efficiency at that concentration was over 90%. The effects of selenazole on viral replication were greatest when this agent was present at the time of viral infection. The removal of selenazole from the medium of infected cells did not reverse the antiviral effect against vaccinia virus, but there was a gradual resumption of viral replication in cells infected with parainfluenza type 3 or herpes simplex virus type 1 (strain KOS). However, the antiviral activity of ribavirin against the same viruses was reversible when the drig was removed.
selenazole-4-carboxamide), were studied against selected DNA and RNA viruses. Although the activity of selenazole against different viruses varied, it was significantly more potent than ribavirin and tiazofurin against all tested representatives of the families Paramyxoviridae (parainfluenza virus type 3, mumps virus, measles virus), Reoviridae (reovirus type 3), Poxviridae (vaccinia virus), Herpes- viridae (herpes simplex virus types 1 and 2), Togaviridae (Venezuelan equine encephalomyelitis virus, yellow fever virus, Japanese encephalitis virus), Bunyaviridae (Rift Valley fever virus, sandfly fever virus [strain Sicilian], Korean hemorrhagic fever virus), Arenaviridae (Pichinde virus), Picornaviridae (coxsackieviruses B1 and B4, echovirus type 6, encephalomyocarditis virus), Adenoviridae (adenovirus type 2), and Rhabdoviridae (vesicular stomatitis virus). The antiviral activity of selenazole was also cell line dependent, being greatest in HeLa, Vero-76, and Vero E6 cells. Selenazole was relatively nontoxic for Vero, Vero-76, Vero E6, and HeLa cells at concentrations of up to 1,000 ,g/ml. The relative plating efficiency at that concentration was over 90%. The effects of selenazole on viral replication were greatest when this agent was present at the time of viral infection. The removal of selenazole from the medium of infected cells did not reverse the antiviral effect against vaccinia virus, but there was a gradual resumption of viral replication in cells infected with parainfluenza type 3 or herpes simplex virus type 1 (strain KOS). However, the antiviral activity of ribavirin against the same viruses was reversible when the drig was removed.
A novel selenazole carboxamide nucleoside, 3 (2-a-D-ribofuranosylselenazole-4-carboxamide) ( Fig. 1) , has recently been synthesized in our laboratory (34) . Its antiviral activity has not been previously evaluated, although our preliminary studies indicated that selenazole 3 possesses significant antitumor effects (34) . Selenazole was designed as an analog of tiazofurin 2 (2-P-D-ribofuranosylthiazole-4-carboxamide).
Preliminary studies of tiazofurin 2 (33) indicated that it possesses a spectrum of antiviral activity in cell culture similar to, but somewhat less potent than, that of ribavirin I (1-P-D-ribofurant Contribution no. 1669, Army Research Program on Antiparasitic Drugs. osyl-1,2,4-triazole-3-carboxamide) and that it has a significant activity against several experimental neoplasms, including those of the lung (15, 18, 26) .
Ribavirin, a related ribofuranosylcarboxamide, has a broad spectrum of antiviral activity (32) , both in vitro (2, 14, 20, 24) and in vivo (13, 16, 19, 31, 37) , and is currently under clinical evaluation for safety and efficacy in humans. Recent studies have shown that ribavirin is remarkably effective clinically against influenza A and B (17, 21) , hepatitis (23) , and respiratory syncytial virus infection (11) . These recent studies in humans have renewed considerable inter- Table 3 , drugs were prepared as described below and adjusted to pH 7.3.
Determination of VR. Vero or HeLa cells were inoculated into 96-well culture plates (Corning) at a concentration of 5 x 104 cells per 0.2 ml per well and cultured for 24 h at 37°C in 5% CO2 to confluency. Cells in the plates were infected with a proper predetermined 50% tissue culture infective dose of virus (0.1 ml per well). Virus was allowed to adsorb for 30 min at 37°C in 5% CO2. After adsorption, the test compounds were added in seven 0.5-log1o dilutions ranging from 5 X 10-3 to 5 x 10-6 M in 0.1 ml of diluent. At each dilution, duplicate wells were used for evaluation of antiviral activity, and single wells were used for determination of cytotoxicity.
The degree of inhibition of virus-induced CPE and drug cytotoxicity was observed microscopically after 72 h of incubation. CPE was scored numerically from 0 (normal control cells) to 4 (100% cell destruction as in virus controls) to calculate a virus rating (VR) as previously reported (30 cells. The compounds were tested using a threefold dilution series of the drug prepared in diluent medium consisting of EMEM-nonessential amino acids, 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), 10 ,ug of gentamicin per ml, and 5% (vol/vol) heat-inactivated FBS. Cells were preincubated with 0.5 ml of drug for 4 h at 37°C in 5% C02, and 100 PFU of virus in the appropriate dilution of drug was adsorbed in 0.2 ml at 37°C in 5% CO2 with shaking every 15 min for a total of 60 min. The plates were then overlaid with Eagle basal medium with Earle salts (without phenol red)-17 mM HEPES-5% heat-inactivated FBS-10 A±g of gentamicin per ml in 0.5% agarose containing the appropriate concentration of drug. Plates were then incubated at 37°C in 5% CO2 for the appropriate time, and the plaques were visualized after staining with neutral red (final concentration, 1:6,000) diluted in Puck saline A containing 5% (vol/vol) heatinactivated FBS and 10 ,ug of gentamicin per ml. The plaques were counted after an additional incubation period of 13 to 24 h. Korean hemorrhagic fever virus was assayed by a modification of the plaque assay described by McCormick et al. (22) , using Linbro 12-well plates containing confluent monolayers of Vero E6 cells. Hantaan virus (50 PFU in 0.1 ml of diluent) was adsorbed at 38°C in 5% CO2 with shaking every 15 min for 60 min. The plates were then overlaid with 0.9 ml of overlay medium (EMEM [without phenol red], 2x nonessential amino acids, 8 mM glutamine, 10% (vol/vol) heat-inactivated FBS, 10 Fg of gentamicin per ml, 0.6% SeaKem ME agarose) containing the appropriate concentration of drug. Plates were then incubated at 38°C in 5% CO2 for 6 days. The plaques were visualized after staining with a solid neutral red overlay (final concentration, 1:6,000) diluted in overlay medium. The ED50 was calculated using a fourparameter logistic curve fitting computer program as described by Rodbard and Hutt (27) .
Concentration, time, and MOI studies. The quantitation of total virus yield was performed on confluent Falcon 24-well plates seeded with Vero cells, using a routine plaque reduction assay (28) . Low multiplicity of infections (MOIs) were used to minimize the production of defective interfering particles during incubation.
Cellular cytotoxicity. HeLa and Vero cells were used for normal cytotoxicity studies. These cells were grown overnight on Linbro 96-well plates until near confluency. The medium was then replaced with growth medium containing one of the three test compounds at a 100-or 1,000-1g/ml concentration. Quadruplet wells were used for each drug concentration, VOL. 24, 1983 on July 6, 2017 by guest http://aac.asm.org/ Downloaded from Tables  1 and 2 , i.e., VR and ED50, do not allow one to determine whether the viral inhibition by selenazole was due to the prevention of viral maturation or due to a masking effect of cellular CPE by the drug. Therefore, the inhibition of the production of infectious virus by various amounts of selenazole was determined in Vero cells infected with four different viruses: HSV-1, Para-3, VV, and VSV. Data presented in Fig. 2 show a concentration-dependent inhibition of infectious virus production by selenazole of HSV-1, VV, and Para-3. However, the data indicate no inhibition of VSV replication in Vero cells by this drug.
The concentration effect of selenazole was linear and broad against VV and HSV-1 (KOS) over a 3-log1o dilution but very abrupt and narrow with Para-3. This seems to reflect the observed CPE in Vero cells. Against Para-3, an almost all-or-nothing response was seen; however, against VV and HSV-1 (KOS), diminishing numbers and sizes of plaques with higher selenazole concentrations were observed. Effect of the time of selenazole addition on the inhibition of viral replication. In the studies described above, selenazole was added immediately after viral adsorption, and the cells were incubated in the presence of the drug until the cultures were assayed. To elucidate the in vitro time dependency of the antiviral activity of selenazole, the effects of adding selenazole before and after viral infection were evaluated in Vero cells. In addition, the reversibility of the antiviral activity of selenazole was studied by removing the drug at various times after viral infection ( Table 4 ). The data indicate that when selenazole was added up to 24 h before infection of Vero cells, no significant time dependency existed against VV and Para-3; both were inhibited during any exposure time by over 99%. However, HSV-1 (KOS) seemed to show a moderate time dependency to selenazole under these test conditions. Under similar growth conditions, with a low MOI (0.004) and with virus incubated in the presence of selenazole at a concentration of M, the simultaneous addition of selenazole and virus caused only about 60% HSV-1 inhibition. Para-3 was inhibited by 100o, and VV was inhibited by 95% (Fig. 2) . When added up to 8 h postinfection, selenazole still showed over 99% inhibition against VV and Para-3 and 60% inhibition against HSV-1 (KOS). The removal of selenazole after 4 and 8 h postinfection caused a moderate loss of its antiviral activity against HSV-1 and Para-3 but not against VV. Again, replication of VSV in Vero cells was not affected by selenazole. In general, selenazole has a much better antiviral activity than does ribavirin as measured with the parameters calculated in Table 4. The potent antiviral effect of ribavirin against VV (Table 4) has been proposed by VOL. 24, 1983 on July 6, 2017 by guest http://aac.asm.org/ Downloaded from ANTIMICROB. AGENTS CHEMOTHER. several investigators (10, 29) to be due to the inhibition of the specific capping mechanism of its mRNA.
Effect of MOI on antiviral activity. Vero cells were infected at various MOIs (0.007 to 5) with HSV-1, Para-3, VV, and VSV. Figure 3 shows the results of the inhibition of total virus yield in the presence of a constant 
DISCUSSION
The experiments in this study were designed so that all three nucleosides were tested in the same microplate against one virus in a single cell line. Thus, for a given experiment, the following parameters were constant: (i) the number of times the cells were passaged, (ii) the drug lot and dilution used, (iii) the conditions under which the virus pool was frozen and thawed, and (iv) the amount of virus (50%o tissue culture infective dose units) added to each microplate well.
Our results indicate that selenazole has a broad-spectrum antiviral activity against both DNA and RNA viruses. Of the DNA viruses studied, the representatives of the families Poxviridae (VV) and Herpesviridae (HSV-1, HSV-2) were inhibited most, but the greatest antiviral activity of selenazole was observed against the representatives of RNA viruses, particularly the families Paramyxoviridae (Para-3, mumps virus, measles virus), Reoviridae (reovirus type 3), Togaviridae (VEE, YF, JE), Bunyaviridae (Rift Valley fever virus, sandfly fever virus [Sicilian], Korean hemorrhagic fever virus), and Arenaviridae (Pichinde virus). Good, although cell-dependent, antiviral activity was measured in the families Adenoviridae (Ad2), Picomaviridae (coxsackieviruses Bi and B4), and Rhabodoviridae (VSV).
Selenazole has been observed to affect the reproduction of both DNA and RNA viruses in several parameters. The plaque number, plaque size, and titer of released virus, as well as intracellular virus production, were all reduced. This antiviral activity seems to be cell-line dependent, being most effective in HeLa cells. The phenomenon that a compound may be relatively ineffective against a particular virus in one cell line but exhibit high activity in another is a common observation (5, 32) .
These preliminary studies also may indicate that the antiviral activity of selenazole is both virucidal (against VV) and virustatic (against Para-3 and HSV-1), depending upon the virus and cell line used. Also, the pretreatment use of selenazole seems to enhance its antiviral activity against virustatic species, such as HSV-1 (Tables 1 and 2; Fig. 3) .
The activity of an antiviral agent in cell culture depends on several biological processes: (i) cell membrane permeability, (ii) intracellular conversion of the drug to its active or inactive form by cellular enzymes, and (iii) selective recognition of the drug by virus-induced or cell enzymes (6, 9, 38) . The slightly lower VR values in Vero cells against adenoviruses and picomaviruses do not seem to be caused by the inability of selenazole to penetrate the cell membrane, since other viruses are effectively inhibited in these cells. More fundamental biochemical processes relating to the permissiveness or nonpermissiveness of the cell-virus assay systems seem to be more likely causes for these variations.
Selenazole is nontoxic to Vero, Vero-76, Vero E6, LLC-MK2, and HeLa cells in 1,000-Rug/ml quantities (highest concentration tested). The lack of cytotoxicity was confirmed by microscopic observation and crystal violet or neutral red staining procedures during VR and ED50 assay readings. However, when cytotoxicity was measured with relative plating efficiency, about 30% of the cells were not able to divide after 3 days of exposure with 1,000 ,ug of selenazole per ml. Although tiazofurin and ribavirin show relatively equal antiviral potency, the antiviral activity of selenazole was noticeably better than either agent against all viruses tested in this study. However, all three agents possess a somewhat similar antiviral spectrum. It appears that selenazole exerts a greater antiviral inhibitory effect over a longer period of time than does ribavirin (Table 4) .
These preliminary findings and the marked antiviral effects of selenazole warrant a further evaluation of its efficacy in other cell-virus assay systems and its potential in vivo usefulness. Further studies are planned to elucidate the antiviral mechanism of selenazole in different cell-virus assay systems and animal virus models. 
